The epidemiological impact of antiretroviral use predicted by mathematical models: A review

被引：75

作者：

Baggaley R.F. ^{[1
]}

Ferguson N.M. ^{[1
]}

Garnett G.P. ^{[1
]}

机构：

[1] Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, Norfolk Place

来源：

Emerging Themes in Epidemiology | / 2卷 / 1期

关键词：

Viral Rebound; Epidemiological Impact; Drug Resistance Evolution; Sexual Partner Change; Treatment Uptake Rate;

D O I：

10.1186/1742-7622-2-9

中图分类号：

学科分类号：

摘要：

This review summarises theoretical studies attempting to assess the population impact of antiretroviral therapy (ART) use on mortality and HIV incidence. We describe the key parameters that determine the impact of therapy, and argue that mathematical models of disease transmission are the natural framework within which to explore the interaction between antiviral use and the dynamics of an HIV epidemic. Our review focuses on the potential effects of ART in resource-poor settings. We discuss choice of model type and structure, the potential for risk behaviour change following widespread introduction of ART, the importance of the stage of HIV infection at which treatment is initiated, and the potential for spread of drug resistance. These issues are illustrated with results from models of HIV transmission. We demonstrate that HIV transmission models predicting the impact of ART use should incorporate a realistic progression through stages of HIV infection in order to capture the effect of the timing of treatment initiation on disease spread. The realism of existing models falls short of properly reproducing patterns of diagnosis timing, incorporating heterogeneity in sexual behaviour, and describing the evolution and transmission of drug resistance. The uncertainty surrounding certain effects of ART, such as changes in sexual behaviour and transmission of ART-resistant HIV strains, demands exploration of best and worst case scenarios in modelling, but this must be complemented by surveillance and behavioural surveys to quantify such effects in settings where ART is implemented. © 2005 Baggaley et al; licensee BioMed Central Ltd.

引用

共 83 条

[41]

Garnett G., Bartley L., Cameron D., Anderson R., Both a 'magic bullet' and good aim are required to link public health interests and health care need in HIV infection, Nat Med, 6, 3, pp. 261-262, (2000)

[42]

Paredes R., Mocroft A., Kirk O., Lazzarin A., Barton S., Van Lunzen J., Katzenstein T., Antunes F., Lundgren J., Clotet B., Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study, Arch Intern Med, 160, pp. 1123-1132, (2000)

[43]

Descamps D., Flandre P.V.C., Peytavin G., Meiffredy V., Collin G., Delaugerre C., Robert-Delmas S., Bazin B., Aboulker J., Et al., Mechanisms of virologic failure in previously untreated HIVinfected patients from a trial of induction-maintenance therapy, JAMA, 283, pp. 205-211, (2000)

[44]

Garnett G.P., Bartley L., Grassly N.C., Anderson R.M., Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings, Nat Med, 8, 7, pp. 651-654, (2002)

[45]

Koopman J.S., Jacquez J.A., Welch G.W., Simon C.P., Foxman B., Pollock S.M., Barth-Jones D., Adams A.L., Lange K., The role of early HIV infection in the spread of HIV through populations, J Acquir Immune Defic Syndr Hum Retrovirol, 14, 3, pp. 249-258, (1997)

[46]

Sungkanuparph S., Vibhagool A., Mootsikapun P., Chetchotisakd P., Tansuphaswaswadikul S., Bowonwatanuwong C., Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis, AIDS, 17, 14, pp. 2129-2131, (2003)

[47]

Laurent C., Diakhate N., Gueye N.F., Toure M.A., Sow P.S., Faye M.A., Gueye M., Laniece I., Toure Kane C., Liegeois F., Et al., The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study, AIDS, 16, 10, pp. 1363-1370, (2002)

[48]

Guidelines for the Use of ARV Agents in HIV-infected Adults and Adolescents, (2002)

[49]

Barkan S.E., Melnick S.L., Preston-Martin S., Weber K., Kalish L.A., Miotti P., Young M., Greenblatt R., Sacks H., Feldman J., The Women's Interagency HIV Study, Epidemiology, 9, 2, pp. 117-125, (1998)

[50]

Moore R.D., Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV clinical practice cohort, J Acquir Immune Defic Syndr Hum Retrovirol, 17, 1 SUPPL., (1998)

← 1 2 3 4 5 6 7 8 9 →